Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Olodaterol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 known ✓ | P07550 | 19/20 | 1.00 |
| ▸ | ADRB1 | P08588 | 17/20 | 1.00 |
| ▸ | CHRM2 | P08172 | 1/20 | 1.00 |
| ▸ | HTR1A | P08908 | 1/20 | 1.00 |
| ▸ | ADRA2A | P08913 | 1/20 | 1.00 |
| ▸ | HTR2A | P28223 | 1/20 | 1.00 |
| ▸ | SLC6A4 | P31645 | 1/20 | 1.00 |
| ▸ | ADRA1A | P35348 | 1/20 | 1.00 |
| ▸ | PTGS2 | P35354 | 1/20 | 1.00 |
| ▸ | HTR2B | P41595 | 1/20 | 1.00 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 1.00 |
| ▸ | PDE4D | Q08499 | 1/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Olodaterol SCHEMBL29737213 | 1.00 | ADRB2 (1.00) | ADRB2ADRB1CHRM2HTR1AADRA2A | |
| Olodaterol SCHEMBL140805 | 1.00 | ADRB2 (1.00) | ADRB2ADRB1CHRM2HTR1AADRA2A | |
| Olodaterol SCHEMBL560926 | 1.00 | ADRB2 (1.00) | ADRB2ADRB1CHRM2HTR1AADRA2A | |
| Olodaterol SCHEMBL29371816 | 0.99 | ADRB1 (1.00) | ADRB2ADRB1CHRM2HTR1AADRA2A | |
| Olodaterol SCHEMBL152331 | 0.99 | ADRB1 (1.00) | ADRB2ADRB1CHRM2HTR1AADRA2A | |
| Olodaterol SCHEMBL560669 | 0.99 | ADRB1 (1.00) | ADRB2ADRB1CHRM2HTR1AADRA2A | |
| Olodaterol SCHEMBL561592 | 0.95 | ADRB2 (0.90) | ADRB2ADRB1CHRM2HTR1AADRA2A | |
| Olodaterol SCHEMBL561364 | 0.94 | ADRB2 (0.89) | ADRB2ADRB1CHRM2HTR1AADRA2A | |
| Olodaterol SCHEMBL560886 | 0.94 | ADRB2 (0.89) | ADRB2ADRB1CHRM2HTR1AADRA2A | |
| Olodaterol SCHEMBL4219120 | 0.94 | ADRB2 (0.89) | ADRB2ADRB1CHRM2HTR1AADRA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1490 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4739295-A1 | AN INHALABLE FORMULATION OF FLUTICASONE PROPIONATE AND ALBUTEROL SULFATE FOR THE TREATMENT OF ASTHMA | Norton (Waterford) Limited (IE) | 2026-05-13 | — | — | EP | claimed |
| EP-4739294-A1 | AN INHALABLE FORMULATION OF FLUTICASONE PROPIONATE AND ALBUTEROL SULFATE FOR THE TREATMENT OF ASTHMA | Norton (Waterford) Limited (IE) | 2026-05-13 | — | — | EP | claimed |
| EP-4255391-B1 | LUMINOL FOR USE IN THE TREATMENT OF SEQUELAE OF A SARS-COV-2 INFECTION | METRIOPHARM AG (CH) | 2026-05-06 | — | — | EP | claimed |
| US-12616803-B2 | Apparatus for dispensing inhalant medicament | METOPI PHARMACEUTICALS, INC. (US) | 2026-05-05 | — | — | US | claimed |
| US-20260102344-A1 | METERED DOSE INHALERS AND SUSPENSION COMPOSITIONS | KINDEVA DRUG DELIVERY LP (US) | 2026-04-16 | — | — | US | claimed |
| EP-4722714-A1 | SIMULTANEOUS ANALYSIS OF FOOD-BORNE DOPING SUBSTANCES USING LIQUID CHROMATOGRAPHY-MASS SPECTROMETRY (VFD: VACCINE FOR FOODBORNE DOPING) | Korea Institute of Science and Technology (KR) | 2026-04-08 | — | — | EP | claimed |
| US-20260069601-A1 | PHARMACEUTICAL COMPOSITION FOR INHALATION FOR PREVENTING OR TREATING RESPIRATORY DISEASE | LEXENPHARM SUZHOU LTD (CN) | 2026-03-12 | — | — | US | claimed |
| US-12569401-B2 | Elongate form medicament carrier and medicament dispenser | MERXIN LTD (GB) | 2026-03-10 | — | — | US | claimed |
| EP-4699655-A2 | COMPOUNDS | TMEM16A LIMITED (GB) | 2026-02-25 | — | — | EP | claimed |
| US-20260021077-A1 | USE OF DEXPRAMIPEXOLE FOR THE TREATMENT OF MODERATE TO SEVERE ASTHMA | ARETEIA THERAPEUTICS, INC. (US) | 2026-01-22 | — | — | US | claimed |
| WO-2022047047-A1 | INHALABLE THERAPEUTIC AGENTS | CILA THERAPEUTIC INC. (US) | 2022-03-03 | — | — | WO | claimed |
| WO-2020249956-A9 | MODULATORS OF TMEM16A FOR TREATING RESPIRATORY DISEASE | TMEM16A LIMITED (GB) | 2022-03-03 | — | — | WO | claimed |
| WO-2022045995-A1 | A PROCESS FOR THE PREPARATION OF DRY POWDER COMPOSITIONS FOR INHALATION | Arven Ilac Sanayi Ve Ticaret Anonim Sirketi (TR) | 2022-03-03 | — | — | WO | claimed |
| CN-114040750-A | Inhalable bronchodilator sustained-release composition for treating pulmonary diseases | 盈擘医药股份有限公司 | 2022-02-11 | — | — | CN | claimed |
| CN-114028364-A | Oldaterol inhalation solution | 南京华盖制药有限公司 | 2022-02-11 | — | — | CN | claimed |
| WO-2022031956-A1 | USE OF DEXPRAMIPEXOLE FOR THE TREATMENT OF MODERATE TO SEVERE ASTHMA | KNOPP BIOSCIENCES LLC (US) | 2022-02-10 | — | — | WO | claimed |
| US-20220040154-A1 | USE OF DEXPRAMIPEXOLE FOR THE TREATMENT OF MODERATE TO SEVERE ASTHMA | ARETEIA THERAPEUTICS, INC. | 2022-02-10 | — | — | US | claimed |
| EP-3946268-A1 | INHALED STATINS AS BRONCHODILATORS TO IMPROVE LUNG FUNCTION IN RESPIRATORY DISEASES | The Regents of The University of California (US) | 2022-02-09 | — | — | EP | claimed |
| US-20220031712-A1 | PREPARATION OF A PHARMACEUTICAL COMPOSITION OF OLODATEROL AND BUDESONIDE | Huang, Cai Gu (US) | 2022-02-03 | — | — | US | claimed |
| CN-113993511-A | Methods and formulations for treating visual disorders | 杰尼视界公司 | 2022-01-28 | — | — | CN | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260069601-A1 | PHARMACEUTICAL COMPOSITION FOR INHALATION FOR PREVENTING OR TREATING RESPIRATORY DISEASE | ADRB2, ADRB3, CHRM3 | ADRB2 1/4885ADRB1 8/4885CHRM2 13/4885 |
| US-20260102344-A1 | METERED DOSE INHALERS AND SUSPENSION COMPOSITIONS | ADRA1D, CHRND, ADRB2 | ADRB2 3/4885ADRB1 14/4885CHRM2 108/4885 |
| US-12616803-B2 | Apparatus for dispensing inhalant medicament | SET, FHIT, FZD7 | ADRB2 1156/4885ADRB1 1763/4885CHRM2 1870/4885 |
| US-20260021077-A1 | USE OF DEXPRAMIPEXOLE FOR THE TREATMENT OF MODERATE TO SEVERE ASTHMA | NR3C2, NR3C1, HSD11B2 | ADRB2 5/4885ADRB1 21/4885CHRM2 123/4885 |
| US-12569401-B2 | Elongate form medicament carrier and medicament dispenser | SAMM50, MTREX, RPL23 | ADRB2 2736/4885ADRB1 3488/4885CHRM2 4507/4885 |
| US-20220040154-A1 | USE OF DEXPRAMIPEXOLE FOR THE TREATMENT OF MODERATE TO SEVERE ASTHMA | EPX, CMA1, TSLP | ADRB2 65/4885ADRB1 107/4885CHRM2 90/4885 |
| US-20220031712-A1 | PREPARATION OF A PHARMACEUTICAL COMPOSITION OF OLODATEROL AND BUDESONIDE | ADRB3, ADRB1, ADRB2 | ADRB2 3/4885ADRB1 2/4885CHRM2 73/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.